OncoMatch/Clinical Trials/NCT06476184
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Is NCT06476184 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Carboplatin and Paclitaxel for ovarian cancer.
Treatment: Carboplatin · Paclitaxel — SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Grade: high-grade
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, paclitaxel) — neo-adjuvant, first-line
Treated with 3 to 4 neo-adjuvant cycles of standard 3-weekly carboplatin-paclitaxel regimen in first-line setting
Cannot have received: VEGF inhibitor (bevacizumab)
Previous treatment with bevacizumab during initial standard neo-adjuvant chemotherapy
Cannot have received: investigational agent
Treatment with other investigational agents in clinical trials.
Lab requirements
Blood counts
Hemoglobin ≥8 g/dL without red blood cell transfusion within 3 weeks before the blood work; ANC ≥1500 cells/mm3; Platelet count ≥100,000/mm3
Kidney function
Creatinine clearance ≥40 mL/min/1.73 m2 (measured or estimated, ideally with CKD-EPI formula)
Liver function
AST and ALT ≤2.5 × ULN, or ≤5 × ULN in context of liver metastases; total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert's); albumin ≥3 g/dL
Adequate organ and bone marrow function for weekly-dense chemotherapy: red blood cells (baseline Hemoglobin ≥8 g/dL without red blood cell transfusion within 3 weeks before the blood work), white blood cells (Absolute neutrophil count (ANC) ≥1500 cells/mm3) and platelets (Platelet count ≥100,000/mm3), Adequate renal and liver functions: AST and ALT ≤2.5 × ULN, or ≤5 × ULN in context of liver metastases; total bilirubin ≤1.5 × ULN (≤3 × ULN if Gilbert's); albumin ≥3 g/dL; Creatinine clearance ≥40 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06476184 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGF inhibitor, investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages